Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Therapeutic treatment with Y-320 (0
It induced tumor regression in mouse xenograft tumor models driven by Bcr-Abl(WT) or the mutants and significantly improved the survival of mice bearing an allograft leukemia model with Ba/F3 cells harboring Bcr-Abl(T315I)
dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types
CAS Number: 543730-41-2
Reversine Catalog No.:M10364-10 Therapeutic treatment with Y-320 (0Reversine is a small molecule developed by the group of Peter G. Schultz, used for stem cell dedifferentiation. Reversine is also a novel Aurora kinases inhibitor that inhibits colony formation of human acute myeloid leukemia cells. Reversine inhibits the phosphorylation of histone H3, a direct downstream target of Aurora kinases. Similarly to the Aurora kinase inhibitor VX 680, reversine inhibited colony formation of leukemic cells from patients with